BIOMARKER-DRIVEN DRUG DEVELOPMENT
Achieve your regulatory milestone faster with better decision-making and less re-work.
Harness the full power of metabolomics for your biomarker-driven drug development with the industry’s broadest and most precise metabolite discovery platform.
WhitepaperBiomarker-Driven Drug Development: Five Translational Insights Key to a Successful First-In-Human (FIH) Study
GET INSIGHTS FASTER
Go beyond all other -omics
Inform adaptive trial design strategies and responses in real-time.
Dynamically monitor and optimize dose-response by tracking prodromal signals of efficacy and safety.
Optimize eligibility criteria by proactively identifying responder/non-responder baseline characteristics.
Maintain trial quality by monitoring patient compliance, subject outliers and potential drug-drug interactions.
Strengthen post-market surveillance with a differentiated drug profile and competitor analysis.
Increase drug development success rate and accelerate the availability of new therapeutics.